HIV Infections Clinical Trial
Official title:
Early Versus Delayed Routine HIV Testing in Connecticut Jails
The objective of this non-randomized, controlled, trial is to evaluate the optimal time to approach newly incarcerated jail inmates for routine opt-out HIV testing in a manner that maximizes the number of individuals able to demonstrate capacity to consent and willingness to receive HIV testing.
Primary outcome: proportion of individuals in each assigned group that agree to be swabbed
for HIV testing and are able to consent to the study.
The prevalence of HIV infection in the United States is four times greater in correctional
settings compared to the general population. Because prisons and jails house a population
facing a disproportionate share of the burden of HIV infection, these facilities serve as
important sites for the testing and treatment of HIV. The Center for Disease Control and
Prevention's recent recommendations to implement routine opt-out HIV testing in all
healthcare settings presents an important challenge and opportunity to correctional
institutions. By effectively implementing routine opt-out testing, correctional facilities
can expand HIV testing to one of society's most at-risk populations. Subsequently, testing
can lead to appropriate access to counseling and treatment both within the correctional
setting and upon release into the community.
Although jails interact with a larger number of individuals at risk for HIV infection than
do prisons, they also pose unique logistical and health-related constraints in several
important ways that impact HIV testing strategies. Jail populations experience short periods
of incarceration and high rates of turnover with many-fold greater admissions and
discharges. Jails also house individuals with higher rates of acute intoxication from
psychoactive drugs, uncontrolled mental illness, and suicidal behavior. The suicide rate in
jails is three times that in state prisons; nearly a quarter of these suicides take place
within the first 48 hours of admission. Furthermore, the individuals who enter jails have
higher recent risk behaviors for HIV than those in prisons.
Given these considerations, a major challenge to implementing routine opt-out HIV testing in
jails is choosing the optimal time to conduct testing. The timing of delivering
non-emergent, traumatically emotional health information (such as a preliminary positive
result in an asymptomatic patient) must be carefully considered. Recently incarcerated
inmates might be too intoxicated or psychologically distressed to demonstrate capacity to
consent to or opt out of routine testing, and may be unprepared to consider and respond to
the consequences of a preliminary positive HIV test result. Likewise, the challenge with
postponing testing is that many individuals experience very short stays in jail, with
approximately one-third leaving within 48 hours, followed by further attrition daily for the
first week and may lose the opportunity for getting life-saving information in a timely
manner.
Therefore, the objective of this study is to evaluate the optimal time to approach newly
incarcerated jail inmates for routine opt-out HIV testing in a manner that maximizes the
number of individuals able to demonstrate capacity to consent and willingness to receive HIV
testing.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |